Document is current
Any future updates will be listed below
-
Authors
Kleerekooper, I. https://orcid.org/0000-0001-6456-9034
Del Porto, L.
Dell’Arti, L.
Guajardo, J.
Leo, S.
Robson, A. G.
Trip, S. A.
Petzold, A.
Plant, G. T.
Holder, G. E.
-
Funding
Funding for this research was provided by:
European Committee for Treatment and Research in Multiple Sclerosis
UCLH Biomedical Research Centre
National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology
- License Information
-
More Information
Article History
Received: 24 November 2021
Accepted: 15 August 2022
First Online: 26 September 2022
Declarations
:
: IK, LDA, LDP, JG, SL, AR, SAT, GTP and GEH report no disclosures. AP reports personal fees from Novartis, Heidelberg Engineering, Zeiss, grants from Novartis, outside the submitted work; and is part of the steering committee of the OCTiMS study which is sponsored by Novartis and the Angio-OCT steering committee which is sponsored by Zeiss. He does not receive compensation for these activities.
: Ethical approval for this study was obtained from the Queen Square London Ethics committee (Number 10/H0716/72) and hospital R&D (FRAC0001). Written informed consent for participation and publication was obtained from all individual participants included in the study.
